美股异动丨阿斯利康涨约3.7%，Q3核心每股盈利超预期

Core Viewpoint - AstraZeneca (AZN.US) reported a strong performance in Q3, with total revenue increasing by 12% year-over-year to $15.191 billion, driven by robust sales of key cancer and diabetes drugs [1] Financial Performance - Total revenue for Q3 reached $15.191 billion, marking a 12% year-over-year growth [1] - Core earnings per share (EPS) were $2.38, exceeding market expectations of $2.27 [1] Future Guidance - The company reaffirmed its full-year revenue growth target of high single digits and core EPS growth of low double digits, aligning with market expectations [1] - AstraZeneca plans to announce a full-year dividend of $3.20 per share for 2025, up from $3.10 last year [1]